1Veronesi U, Cascinellin, Marianin L, et al. Twenty-year follow up of a randomized study comparing breast-con- serving surgery with radical mastectomy for early breast cancer[J]. N Engl J Med,2002,347(16):1227-1232. 被引量：1
2Fisher B, Anderson S, Bryant J, et al. Twenty-year fol- low-up of a randomized trail comparing total mastecto- my,lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med,2002,347(16) : 1223-1241. 被引量：1
3van Dongen JA, Voogd AC, Fentiman IS, et al. Long- term results of a randomized trail comparing breast- conserving therapy with mastectomy .. European Organ- ization for Research and Treatment of Cancer 10801 trial[J]. J Natl Cancer Inst,2000,92(14) :1143-1150. 被引量：1
4Veronesi U, Paganelli G, Viale G, et aL A randomized comparison of sentinel-node biopsy with routine axilla- ry dissection in breast cancer [J]. N Engl J Med,2003, 349(6) :546-553. 被引量：1
5Prosnitz LR, Marks LB. Partial breast irradiation= a cautionary note[J]. Int J Radiat Oncol Biol Phys,2006, 65(2) :319-321. 被引量：1
6Goyal A, Mansel RE. Recent advances in sentinel lymph node biopsy for breast cancer[J]. Curt Opin On- col,2008,20(6) :621-626. 被引量：1
7Huang EH, Tucker Sir, Strom EA, et al. Postmastecto- my radiation improves local regional control and sur- vival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy [ J ]. J Clin Oncol, 2004, 22 ( 23 ) : 4691- 4699. 被引量：1
4Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 1998,351:1451. 被引量：1
5Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HEB2-positive breast cancer. N Engl J Med, 2005, 353: 1673-1684. 被引量：1
6Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med,2001,344(11),783-792. 被引量：1
7Forbes JF, Kennedy J, Pienkowski T, et al. BCIRG 007: randomized phase Ⅲ trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC) [J]. J Clin Oncol, 2006,24(Suppl) : 516. 被引量：1
8Minckwitz CV, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumah treatment: The TBP phase Ⅲ study (GBG 26/BIG 3-05)[J]. J Clin Oncol, 2008,26 (Suppl), 1025. 被引量：1
9Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J]. N Engl J Med, 2005,353(16):1659-1672. 被引量：1
10Romond EH, Perez EA. Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer [J].N Engl J Med,2005, 353 (16):1673-1684. 被引量：1
